Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children

Vaccine

Volumn 34, Issue 4, 2016, Pages 474-478

  Kendall, Brian A ^a   Dascomb, Kristin K ^a,b   Mehta, Rajesh R ^b   Stockmann, Chris ^a   Mason, Edward O ^c   Ampofo, Krow ^a   Pavia, Andrew T ^a   Byington, Carrie L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b INTERMOUNTAIN HEALTHCARE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Invasive pneumococcal disease; Pneumococcal vaccines; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; VACCINE;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CHILD; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; DEMOGRAPHY; DRUG EFFECT; FEMALE; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; SEX; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; ADOLESCENT; CLASSIFICATION; INFANT; MICROBIOLOGY; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; UTAH;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; UTAH; VACCINES, CONJUGATE;

EID: 84952976162     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.010     Document Type: Article

References (29)

1. Moore M.R., Link-Gelles R., Schaffner W., Lynfield R., Lexau C., Bennett N.M., et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015, 15(March (3)):301-309.
2. Stockmann C., Byington C.L. PCV13 in the USA: early successes and potential challenges. Lancet Infect Dis 2015, 15(March (3)):254-256.
3. Ghaffar F., Barton T., Lozano J., Muniz L.S., Hicks P., Gan V., et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004, 39(October (7)):930-938.
4. Ampofo K., Pavia A.T., Stockmann C.R., Blaschke A.J., Weng H.Y., Korgenski K.E., et al. Evolution of the epidemiology of pneumococcal disease among Utah children through the vaccine era. Pediatr Infect Dis J 2011, 30(December (12)):1100-1103.
5. Li S.T., Tancredi D.J. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010, 125(January (1)):26-33.
6. Grijalva C.G., Nuorti J.P., Zhu Y., Griffin M.R. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis 2010, 50(March (6)):805-813.
7. Lalitha M.K., Thomas K., Kumar R.S., Steinhoff M.C. Serotyping of Streptococcus pneumoniae by coagglutination with 12 pooled antisera. J Clin Microbiol 1999, 37(January (1)):263-265.
8. Schuck-Paim C., Taylor R., Lindley D., Klugman K.P., Simonsen L. Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake. Vaccine 2013, 31(December (50)):5983-5988.
9. Ampofo K., Pavia A.T., Stockmann C., Hersh A.L., Bender J.M., Blaschke A.J., et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the PCV7 Era. Pediatr Infect Dis J 2011, 3(November):228-234.
10. Rueda A.M., Serpa J.A., Matloobi M., Mushtaq M., Musher D.M. The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore) 2010, 89(September (5)):331-336.
11. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005 Sep 16;54(36):893-97.
12. Centers for Disease Control and Prevention. Vaccines and Immunizations. National Immunization Survey. 2015 [cited 1 November 2015]; Available from: http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/tables/11/tab03_antigen_state_2011.pdf.
13. Kendall B.A., Dascomb K.K., Mehta R.R., Mason E.O., Ampofo K., Pombo D.J., et al. Streptococcus pneumoniae serotypes in Utah adults at the end of the PCV7 era. Vaccine 2011, 29(November (49)):9123-9126.
14. Millar E.V., O'Brien K.L., Watt J.P., Bronsdon M.A., Dallas J., Whitney C.G., et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006, 43(July (1)):8-15.
15. Olarte L., Ampofo K., Stockmann C., Mason E.O., Daly J.A., Pavia A.T., et al. Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7. Pediatrics 2013, 132(July (1)):e17-e24.
16. Poolman J., Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011, 10(March (3)):307-322.
17. Paradiso P.R. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011, 52(May (10)):1241-1247.
18. Yeh S.H., Gurtman A., Hurley D.C., Block S.L., Schwartz R.H., Patterson S., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126(September (3)):e493-e505.
19. Dunais B., Bruno P., Touboul P., Degand N., Sakarovitch C., Fontas E., et al. Impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae among children attending group daycare in southeastern France. Pediatr Infect Dis J 2015, 34(March (3)):286-288.
20. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6(May (5)):e1000081.
21. Jacobs M.R., Good C.E., Bajaksouzian S., Windau A.R. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008, 47(December (11)):1388-1395.
22. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
23. Stockmann C., Ampofo K., Byington C.L., Filloux F., Hersh A.L., Blaschke A.J., et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah. Pediatrics 2013, 132(September (3)):421-428.
24. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360(January (3)):244-256.
25. Byington C.L., Korgenski K., Daly J., Ampofo K., Pavia A., Mason E.O. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006, 25(March (3)):250-254.
26. Klein S.L., Poland G.A. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013, 31(May (23)):2599-2600.
27. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26(July (29-30)):3551-3555.
28. Wiemken T.L., Carrico R.M., Klein S.L., Jonsson C.B., Peyrani P., Kelley R.R., et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014, (March).
29. Long S.S. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005, 41(July (1)):30-34.